SC 13D/A - NightHawk Biosciences, Inc. (0001476963) (Subject)

SC 13D/A - NightHawk Biosciences, Inc. (0001476963) (Subject)

DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a major university. The program involves process optimization and development of a therapeutic antibody, which Scorpius will manufacture for preclinical studies. The work will be conducted in the Company's state-of-the-art process development lab and cGMP cleanrooms in its Mammalian Building, which is ideally suited for early-stage programs using CHO cell lines. Following process optimization and development, the Co

DURHAM, N.C., March 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been accepted into the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a part of the National Biopharmaceutical Manufacturing Partnership. The BioMap-Consortium has a $20 billion funding ceiling, through which it provides growth funding, as well as streamlined access to servicing government-funded manufacturing programs. The BioMaP-Consortium supports the Biomedical Advanced Research and Development Authority (BARDA) and is comprised of industry partners across the d

DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for gross proceeds of $1,500,000, before deducting underwriting discounts and offering expenses. The Company intends to use the proceeds from the offering for working capital and general corporate purposes. ThinkEquity acted as sole book-running manager for the offering. The offering was made pursuant to an effective shelf registration

DURHAM, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for aggregate gross proceeds of $1,500,000, before deducting underwriting discounts, commissions and offering expenses. All of the shares of common stock were offered by the Company. The offering is expected to close on March 12, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering

DURHAM, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX) ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced that it intends to offer to sell shares of its common stock to the public in an underwritten public offering. All of the shares of common stock are to be sold by the Company. ThinkEquity is acting as sole book-running manager for the offering. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-2512

Estimates Sequential Reduction in the Fourth Quarter of 2023 Operating Loss by Over $3.3 Million or Approximately 30% Compared to the Third Quarter of 2023 Achieves Record Backlog of $9.3 Million DURHAM, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc., ("Scorpius") (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today reported preliminary, unaudited financial results for the fourth quarter of 2023. Jeff Wolf, CEO of Scorpius, stated, "We are firing on all cylinders and currently estimate our preliminary, unaudited revenue for the fourth quarter of 2023 to be in the range of $3.4 million to $3.6 million, which would repres

DURHAM, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences / Scorpius Holdings, Inc. (NYSE American: NHWK; SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it had completed its name change from NightHawk Biosciences, Inc. to Scorpius Holdings, Inc., to better reflect the Company's successful shift into a pure-play, large molecule biomanufacturing CDMO. In connection with the name change, the Company's ticker will change to "SCPX" effective today, February 6, 2024. The name and symbol changes do not affect the Company's share structure or the rights of the Company's shareholders, and no further action will be required by existi

DURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK) ("NightHawk" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the promotion of Joe Payne to President and Chief Operating Officer (COO) of its Scorpius BioManufacturing subsidiary. Payne joined Scorpius in 2023 as VP of Quality and Regulatory Affairs. With a biopharma and pharmaceutical career spanning over 20 years, Payne's recent experience includes leadership roles at CDMOs Tergus Pharma and Alcami Corporation. He has participated in 40+ regulatory inspections and has extensive knowledge of global regulatory agency requirements. In his role as Pr

DURHAM, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK) ("NightHawk" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced it has sold additional none-core IP. Additionally, the Company received proceeds of $2.25 million from a note issued pursuant to the terms of the previously announced divestiture of non-core assets ( the "Note"). The Note bears interest at an annual rate of 1% and, subject to stockholder approval, would be convertible into shares of NightHawk's common stock at $0.39281 per share, an 8% premium to the closing price of the Company's common stock on January 29, 2024. Jeff Wolf, CEO of Nigh

DURHAM, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK) ("NightHawk" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius BioManufacturing subsidiary has been awarded a multimillion-dollar contract to provide process development, analytical, and cGMP manufacturing services for a publicly traded biotech company's Phase 2 clinical program. Jeff Wolf, CEO of NightHawk Biosciences, commented, "We are proud to have been selected to help advance this potentially lifesaving therapy through the clinic. Scorpius has multiple clients with Orphan Drug Designations from the FDA, and our San Antonio facili

8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)

8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)

8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)

8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)

8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)

8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)

8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)

S-3 - NightHawk Biosciences, Inc. (0001476963) (Filer)

424B5 - NightHawk Biosciences, Inc. (0001476963) (Filer)